Polypharmacy and risk of antiretroviral drug interactions among the aging hiv-infected population

Journal of General Internal Medicine

Volumn 28, Issue 10, 2013, Pages 1302-1310

  Holtzman, Carol ^a   Armon, Carl ^b   Tedaldi, Ellen ^c   Chmiel, Joan S ^d   Buchacz, Kate ^e   Wood, Kathleen ^b   Brooks, John T ^e  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b CERNER CORPORATION   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

aging; drug interactions; HIV; polypharmacy

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CLORAZEPATE; DIAZEPAM; FLURAZEPAM; LITHIUM; MEVINOLIN; NELFINAVIR; PAROXETINE; PROTEINASE INHIBITOR; RNA; SERTRALINE; SIMVASTATIN; TRIAZOLAM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGING; ANXIETY; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DATA BASE; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG USE; DYSLIPIDEMIA; ETHNICITY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; POLYPHARMACY; POPULATION; PRESCRIPTION; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AGE DISTRIBUTION; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; RISK FACTORS;

EID: 84885178803     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2449-6     Document Type: Article

References (44)

1. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41(2):194-200.
2. Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ. Pill burden in HIV infection: 20 years of experience. Antivir Ther. 2012;17(5):833-40.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003;362(9377):22-9. (Pubitemid 36835816)
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60. (Pubitemid 28135961)
5. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376(9734):49-62.
6. CDC 2012: Centers for Disease Control and Prevention. HIV Surveillance Report, 2010; vol. 22. http://www.cdc.gov/hiv/topics/surveillance/resources/ reports/. Published March 2012. Accessed June 5, 2012.
7. Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV Infection and Older Americans: The Public Health Perspective. 2012;102:1516-26.
8. Jyrkka J, Vartiainen L, Hartikainen S, Sulkava R, Enlund H. Increasing use of medicines in elderly persons: A five-year follow-up of the Kuopio 75 + Study. Eur J Clin Pharmacol. 2006;62(2):151-8.
9. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55(8):809-17.
10. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol. 2001;51(6):615-22. (Pubitemid 32862751)
11. Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1,756 patients. Drug Saf. 2008;31(6):545-56. (Pubitemid 351693687)
12. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237-53.
13. Lin CF, Wang CY, Bai CH. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: A retrospective computerized screening study. Drugs Aging. 2011;28(3):219-25.
14. Secoli SR, Figueras A, Lebrão ML, de Lima FD, Santos JL. Risk of potential drug-drug interactions among Brazilian elderly: A population-based, cross-sectional study. Drugs Aging. 2010;27(9):759-70.
15. Tamura BK, Bell CL, Inaba M, Masaki KH. Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med. 2012;28(2):217-36.
16. Buchacz K, Baker RK, Palella FJ, Jr., et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65-75.
17. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130-9.
18. Kilbourne A, Justice A, Rabeneck L, Rodriquez-Barradas M, Weissman S. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epi. 2001;54(12):S22-8. (Pubitemid 34019141)
19. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012;26(Suppl 1):S39-53.
20. Rainey PM. HIV drug interactions: the good, the bad, and the other. Ther Drug Monit. 2002;24(1):26-31. (Pubitemid 34106727)
21. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med. 2010;268(6):530-9.
22. Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. 2002;9(4):191-8. (Pubitemid 36903538)
23. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999;39:1-17. (Pubitemid 29222549)
24. Griffin L, Annaert P, Brouwer KL. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci. 2011;100(9):3636-54.
25. Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med. 2009;25(2):221-33.
26. Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992-2002. Int J Clin Pharmacol Ther. 2007;45(12):643-53. (Pubitemid 350268038)
27. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666-71. (Pubitemid 33131567)
28. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol. 2010;10:16.
29. Ibrahim IA, Kang E, Dansky KH. Polypharmacy and possible drug-drug interactions among diabetic patients receiving home health care services. Home Health Care Serv Q. 2005;24(1-2):87-99.
30. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: A study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30(10):911-8. (Pubitemid 47481446)
31. Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507-19.
32. Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull. 1998;45(2):210-3. (Pubitemid 28183947)
33. Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: A retrospective cohort study in the Emilia-Romagna region, Italy. Drugs Aging. 2010;27(12):1019-28.
34. Gianotti N, Galli L, Bocchiola B, et al. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: A large cross-sectional study of HIV-infected patients on antiretroviral therapy. HIV Med. 2013;14(3):153-60.
35. Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3):413-23.
36. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66(9):2107-11.
37. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187-95. (Pubitemid 46072105)
38. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-51.
39. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-3421.
40. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45(12):3445-50. (Pubitemid 33107860)
41. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343-70. (Pubitemid 34713089)
42. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih. gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed February 27, 2013.
43. Kauffman Y, Nair V, Herist K, Thomas V, Weidle PJ. HIV medication therapy management services in community pharmacies. J Am Pharm Assoc. 2012;52(6):e287-91.
44. Baysari MT, Westborrk J, Braithwaite J, et al. The role of computerized decision support in reducing errors in selecting medicines for prescription. Drug Saf. 2011;34(4):289-98.